Sample Procurement and Management Core
采购和管理核心示例
基本信息
- 批准号:7673677
- 负责人:
- 金额:$ 11.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-01 至 2012-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAutoantibodiesAutoimmune ProcessCellsClinicalClinical DataConsentDataDatabasesEnrollmentGoalsHousingHumanHuman Subject ResearchIndividualInterdisciplinary StudyLaboratoriesLifeLupusMeasuresMethodsOklahomaPatientsProcessPurposeQuality ControlRecruitment ActivityReportingResearchResearch PersonnelResearch Project GrantsResourcesRheumatismSamplingSerumServicesSystemic Lupus ErythematosusTestingTransformed Cell Linedata managementdesignhuman subjectmemberrepositoryresearch studysuccess
项目摘要
The goals of the Sample Procurement and Management Core (SPMC) are to optimize,
promote and facilitate the research undertaken by the Center Investigators, as well as to
enhance the interdisciplinary research capabilities between various Center laboratories and to
expedite human subjects research in a meaningful way. The SPMC will provide support to
Center Investigators and other users in terms of providing previously collected, de-identified,
appropriately consented DMA and serum to projects, expanding DMA from existing resources or
isolating additional DMA as needed from EBV-transformed cells lines, testing quality and quantity
of outside and newly generated DMA and serum samples as needed, recruiting and enrolling
fresh samples for project use, measuring autoantibodies in appropriate samples and managing
samples and data for the success of the Oklahoma Rheumatic Disease Research Cores Center
(ORDRCC). As potential collaborators for all Core research projects, the SPMC will be an
integral part of the research team in the execution of research studies, as well as providing
ongoing sample and data management throughout the life of each individual project.
The specific goals of the SPMC include:
1. Facilitate access to human samples for research purposes. This goal includes
serving as a central resource for Cores Center investigators to obtain appropriately
collected DMA, serum, cells, clinical and de-identified clinical data.
2. Facilitate human subject consent, recruitment and compliance. This goal includes
consenting, recruiting and obtaining samples from confirmation rheumatic disease
patients for Core investigator projects, as well as assist with regulatory reporting.
3. Facilitate the compilation and appropriate access to de-identified patient
demographic and clinical data from existing resources and management of
research data for Center Investigators. Consent, recruit and/or obtain samples from
confirmatory lupus subsets or from patients with other systemic autoimmune rheumatic
diseases for feasibility and other projects for key Core investigators.
4. Perform autoantibody testing for appropriate rheumatic disease patient sera.
样品采购和管理核心(SPMC)的目标是优化,
促进和促进中心研究者开展的研究,以及
加强各中心实验室之间的跨学科研究能力,
以一种有意义的方式加速人类受试者的研究。SPMC将提供支持,
中心研究者和其他用户在提供之前收集的、去识别的信息方面,
适当同意DMA和血清项目,扩大DMA从现有资源或
根据需要从EBV转化的细胞系中分离额外的DMA,
外部和新生成的DMA和血清样本(如需要),招募和入组
项目使用的新鲜样本,测量适当样本中的自身抗体,
俄克拉荷马州风湿病核心研究中心成功的样本和数据
(ORDRCC)。作为所有核心研究项目的潜在合作者,SPMC将是一个
研究团队的组成部分,在执行研究研究,以及提供
在每个项目的整个生命周期内持续进行样品和数据管理。
SPMC的具体目标包括:
1.为研究目的获取人体样本提供便利。这一目标包括
作为核心中心研究人员的中心资源,
收集DMA、血清、细胞、临床和去识别临床数据。
2.促进人类受试者同意、招募和依从性。这一目标包括
同意、招募和获取确认风湿性疾病的样本
核心研究者项目的患者,以及协助监管报告。
3.促进汇编和适当访问去识别患者
现有资源的人口统计学和临床数据,
研究中心研究者的研究数据。同意、招募和/或获取样本
或来自其他全身性自身免疫性风湿性关节炎患者
疾病的可行性和其他项目的关键核心研究人员。
4.对适当的风湿病患者血清进行自身抗体检测。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Morris Reichlin其他文献
Morris Reichlin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Morris Reichlin', 18)}}的其他基金
Oklahoma Specialized Center of Research in SLE
俄克拉荷马州系统性红斑狼疮专业研究中心
- 批准号:
7125194 - 财政年份:2002
- 资助金额:
$ 11.39万 - 项目类别:
IRB Inovation at a Private Research Foundation
私人研究基金会的 IRB 创新
- 批准号:
6591618 - 财政年份:2002
- 资助金额:
$ 11.39万 - 项目类别:
BIOMED RES FACIL IMPROV : BONE DENSITY
Biomed RES FACIL IMPROV:骨密度
- 批准号:
6794414 - 财政年份:2002
- 资助金额:
$ 11.39万 - 项目类别:
BIOMED RES FACIL IMPROV : IMMUN DIS
Biomed RES FACIL IMPROV : IMMUN DIS
- 批准号:
6794417 - 财政年份:2002
- 资助金额:
$ 11.39万 - 项目类别:
Oklahoma Specialized Center of Research in SLE
俄克拉荷马州系统性红斑狼疮专业研究中心
- 批准号:
6793968 - 财政年份:2002
- 资助金额:
$ 11.39万 - 项目类别:
Oklahoma Specialized Center of Research in SLE
俄克拉荷马州系统性红斑狼疮专业研究中心
- 批准号:
6531904 - 财政年份:2002
- 资助金额:
$ 11.39万 - 项目类别:
相似海外基金
Defining the cellular origin of pathogenic autoantibodies
定义致病性自身抗体的细胞起源
- 批准号:
EP/Y031091/1 - 财政年份:2024
- 资助金额:
$ 11.39万 - 项目类别:
Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
- 批准号:
MR/Y022947/1 - 财政年份:2024
- 资助金额:
$ 11.39万 - 项目类别:
Research Grant
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
- 批准号:
479128 - 财政年份:2023
- 资助金额:
$ 11.39万 - 项目类别:
Operating Grants
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancer
肿瘤衍生新表位的自身抗体作为生物标志物和免疫 PET 试剂用于小细胞肺癌的早期检测
- 批准号:
10715807 - 财政年份:2023
- 资助金额:
$ 11.39万 - 项目类别:
Role of pharmacological activity of autoantibodies in ME/CFS
自身抗体药理活性在 ME/CFS 中的作用
- 批准号:
MR/Y003667/1 - 财政年份:2023
- 资助金额:
$ 11.39万 - 项目类别:
Research Grant
Pathological Mechanisms of Immune-Mediated Cerebellar Ataxia with Associated Sez6L2 Autoantibodies
免疫介导的小脑共济失调与相关 Sez6L2 自身抗体的病理机制
- 批准号:
10740682 - 财政年份:2023
- 资助金额:
$ 11.39万 - 项目类别:
Pathogenesis of idiopathic nephrotic syndrome: defining the role of B cells and autoantibodies reactive to podocyte proteins
特发性肾病综合征的发病机制:定义 B 细胞和足细胞蛋白反应性自身抗体的作用
- 批准号:
487849 - 财政年份:2023
- 资助金额:
$ 11.39万 - 项目类别:
Operating Grants
Depleting autoantibodies for the treatment of autoimmunity
消耗自身抗体来治疗自身免疫
- 批准号:
10481071 - 财政年份:2022
- 资助金额:
$ 11.39万 - 项目类别:
Pathological Mechanisms of Immune-Mediated Cerebellar Ataxia with Associated Sez6L2 Autoantibodies
免疫介导的小脑共济失调与相关 Sez6L2 自身抗体的病理机制
- 批准号:
10526475 - 财政年份:2022
- 资助金额:
$ 11.39万 - 项目类别:














{{item.name}}会员




